Advice
following a full submission:
mirabegron (Betmiga®) is accepted for use within NHS Scotland.
Indication under review: for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
Mirabegron was associated with modest treatment benefits over placebo in reducing symptoms associated with overactive bladder syndrome, including frequency and incontinence.
Alternative treatments are available at a lower drug acquisition cost.
Download detailed advice151KB (PDF)
Medicine details
- Medicine name:
- mirabegron (Betmiga)
- SMC ID:
- 862/13
- Indication:
- For symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 May 2013